• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities 2013 - Product Image

PCR in Screening and Diagnostics: Market Developments, Growth Areas and Opportunities 2013

  • ID: 2565403
  • June 2013
  • Region: Global
  • 168 Pages
  • BioPharm Reports (VennBio Ltd.)

This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the PCR clinical and diagnostics field.

Its findings include:

- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunities

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the PCR screening and diagnostics field.

Examples include

- PCR Techniques: Which PCR screening and diagnostics techniques are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and diagnostics techniques are growing and which are declining?
- PCR Applications: Which PCR screening and diagnostics applications are the market leaders and what changes do end-users predict over the next three years. Which PCR clinical and diagnostics applications are growing and which are reducing?
- Suppliers: Who are the major company suppliers in the PCR screening and diagnostics field and who do PCR clinical and diagnostics end-users plan to READ MORE >

Executive Summary

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 PCR Activities
2.7 Participants
2.8 Discussion
Figure 2.1 Countries of individuals who participated in PCR 2013 CLIN
Figure 2.2 Global regions of individuals who participated in PCR 2013 CLIN.
Figure 2.3 Organisation types of individuals who participated in PCR 2013 CLIN
Figure 2.4 Fields of individuals who participated in PCR 2013 CLIN
Table 2.1 Countries of individuals who participated in PCR 2013 CLIN
Table 2.2 Global regions of individuals who participated in PCR 2013 CLIN
Table 2.3 Organisation types of individuals who participated in PCR 2013 CLIN

Chapter 3 PCR Techniques

3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion
Figure 3.1 Top ten currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Table 3.1 Currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Figure 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Table 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2013 CLIN
Figure 3.3 Top ten PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 3.3 PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated PCR 2013 CLIN

Chapter 4 PCR Applications

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion
Figure 4.1 Top ten currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Table 4.1 Currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Figure 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Table 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2013 CLIN
Figure 4.3 Top ten PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 4.3 PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

Chapter 5 Companies

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion
Figure 5.1 Top ten PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Table 5.1 PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Figure 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Table 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2013 CLIN
Figure 5.3 Top ten PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 5.3 PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Figure 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN
Table 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2013 To 2016), indicated by individuals who participated in PCR 2013 CLIN

Chapter 6 Preferred Companies and Products

6.1 This Chapter
6.2 Preferred Companies
6.3 Preferred products
6.4 Strengths
6.5 Weaknesses
6.6 Discussion
Figure 6.1 Top ten preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.1 Preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.3 Top ten preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.3 Preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.4 Other preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.4 Other Top preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.5 Top ten strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.5 Strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.7 Top ten weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.7 Weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Figure 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN
Table 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2013 CLIN

Chapter 7 PCR Expenditure and Budgets

7.1 This Chapter
7.2 Current Financial budget
7.3 Future Expenditure
7.4 Future General Budget
Figure 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.3 Cost per sample for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Figure 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN
Table 7.4 The anticipated future breakdown of financial budgets (over the next three years, 2013 To 2016) for PCR studies, indicated by individuals who participated in PCR 2013 CLIN

Chapter 8 Purpose of PCR Use

8.1 This Chapter
8.2 Purpose
8.3 Discussion
Figure 8.1 Top ten reasons for using PCR in the biotechnology industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.2 Top ten reasons for using PCR in clinics or hospitals, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.3 Top ten reasons for using PCR in hospitals, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.4 Top ten reasons for using PCR in the healthcare industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.5 Top ten reasons for using PCR in the pharmaceutical industry, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.6 Top ten reasons for using PCR in research institutes, indicated by individuals who participated in PCR 2013 CLIN
Figure 8.7 Top ten reasons for using PCR in universities, indicated by individuals who participated in PCR 2013 CLIN

Chapter 9 Samples

9.1 This Chapter
9.2 Samples
9.3 Discussion
Figure 9.1 Top ten sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 9.1 Sample types analysed using PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 10 Sample Preparation

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion
Figure 10.1 Top sample preparation methods of PCR users who participated in PCR 2013 CLIN
Table 10.1 Sample preparation methods of PCR users who participated in PCR 2013 CLIN
Figure 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN
Table 10.2 Other sample preparation methods of PCR users who participated in PCR 2013 CLIN

Chapter 11 Therapeutic Areas

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion
Figure 11.1 Top ten therapeutic areas of PCR users who participated in PCR 2013 CLIN
Table 11.1 Therapeutic areas of PCR users who participated in PCR 2013 CLIN
Figure 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN
Table 11.2 Other therapeutic areas of PCR users who participated in PCR 2013 CLIN

Chapter 12 Disease Biomarkers

12.1 This Chapter
12.2 Use of PCR
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion
Figure 12.1 The use of PCR for the study of disease biomarkers, indicated by individuals who participated in PCR 2013 CLIN
Figure 12.2 Principal disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 12.1 Other disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 12.3 Clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 12.2 Other clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 13 Bioinformatics Software

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion
Figure 13.1 Top ten bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
Table 13.1 Bioinformatics software system used for DNA PCR, indicated by users who participated in PCR 2013 CLIN
Figure 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN
Table 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2013 CLIN

Chapter 14 Innovation

14.1 This Chapter
14.2 Required Innovation
14.3 Recent Innovation
14.4 Future Innovation
14.5 Discussion
Figure 14.1 Top ten most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.1 Most required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.3 Top ten recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.3 Recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Figure 14.4 Top ten future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN
Table 14.4 Future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2013 CLIN

Chapter 15 Quality Control

15.1 This Chapter
15.2 Quality Control
15.3 Future Innovation
15.4 Discussion
Figure 15.1 Top ten most commonly used quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN
Table 15.1 Quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2013 CLIN

Chapter 16 PCR Consumables

Chapter 17 Discussion

Chapter 18 Appendices

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos